Back to News
Oct 16, 2025 4:00 PM

Johnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy

On Thursday, Johnson & Johnson (NYSE:JNJ) announced positive topline results from a recent study.

The company’s Phase 3 MajesTEC-3 trial is evaluating Tecvayli (teclistamab-cqyv) in combination with Darzalex Faspro (daratumumab and hyaluronidase-fihj) for patients with relapsed or refractory multiple myeloma who received one to three prior treatments.

After nearly three years of follow-up, the Tecvayli-Darzalex combination significantly improved both progression-free survival (PFS) and overall survival (OS) compared to current standard therapies. The Independent Data ...